IL6 and Charcot-Marie-Tooth disease type 1A: hAAT was previously shown to reduce axon demyelination and secreted IL-6 levels in a mouse model of EAE-induced multiple sclerosis [13], which is consistent with the effects observed in our CMT1A mouse model.